Skip to main
IQV

IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Hlds (IQV) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 53%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IQVIA Holdings is experiencing notable year-over-year growth in its Flexible Solutions Provisioning (FSP), Real World Evidence (RWE), and Clinical Solutions Management Services (CSMS) segments, indicating strong operational performance in Q3. The company is also benefiting from improved decision timelines and a robust pipeline within its commercial segment, largely fueled by recent drug launches. Additionally, IQVIA is projecting a growth rate of over 4% in its Research and Development Solutions segment on a constant currency basis, reflecting a favorable pricing environment and strategic management of contract negotiations.

Bears say

IQVIA Holdings experienced a decline in year-over-year constant currency (CC) growth, which fell to 3.8%, compared to 6.8% in the previous quarter, indicating challenges in maintaining robust revenue growth rates. The company has expressed that it would be dissatisfied with reported revenue growth below 5% for 2026, reflecting a cautious outlook amidst pressures such as margin headwinds from passthroughs and the impact of rising interest rates on earnings. Furthermore, individual segments showed organic CC growth that was uneven, with the Technology and Analytics Solutions (TAS) segment facing the most significant challenges, leading to concerns about the overall ability to sustain positive growth momentum.

IQVIA Hlds (IQV) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 53% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IQVIA Hlds (IQV) Forecast

Analysts have given IQVIA Hlds (IQV) a Buy based on their latest research and market trends.

According to 15 analysts, IQVIA Hlds (IQV) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $230.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $230.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IQVIA Hlds (IQV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.